Sensyne Health receives UK approval for COVID-19 risk prediction tool

Clinical AI company Sensyne Health has received regulatory approval in the UK for its SYNE-COV machine learning algorithm for COVID-19 risk prediction. SYNE-COV analyses over 60 variables in the patient electronic health record to generate a prediction of the likelihood of a COVID-19 positive patient developing severe disease, requiring ventilation or admission to intensive care. It provides the risk prediction, together with an explanation of the result, to help clinicians manage patients admitted to hospital with COVID-19 infection. The SYNE-COV product was developed in collaboration between Sensyne and the Chelsea & Westminster Hospitals NHS Foundation Trust. This is the first algorithm developed from the SENSE clinical and operational algorithm engine to achieve UK regulatory approval.